Abstract
Lung Cancer is the major cause of death all over the world. Statistically, China skilled substantial elevation in the rate of cigarette smokers since past twenty years and a pinnacle in lung carcinoma are further anticipated. Globally, Non-Small Cell Lung Cancer reports around 85% of cases of all pulmonary carcinomas. To ascertain the suitable treatment for Non-Small Cell Lung Cancer, exact staging with the help of computed tomography is very important. Practically, surgery would be the only reconcilable alternative for the cure. Although, 70-80% of the cases of lung cancers at the time of presentation itself develop metastases which are determined during the diagnosis. Personalized Medicine is the prominent practice of medicine that employs the patient’s genetic profile for the prevention, diagnosis and treatment of the disease. Current proceedings in knowing the signaling pathways for cancerous cells and the affinity in these pathways, the significance of biomarkers and different receptors, and the interaction of various cancer promoting genes have assisted in progress of various targeted therapies enhancing the safety and efficacy. This boosts up the patient’s attribute of life. The treatments are focused at genetic adjustments in cancerous cells. Several NSCLC subtypes are related to targetable biomarkers like alteration of Epidermal Growth Factor Receptor or EGFR, the existence of EML-4 and ALK fusion genes, ALK rearrangements or KRAS. The hostility to therapies is enhanced by the C-Met over expression or amplification. The purpose of this context is the treatment of Non Small Cell Lung Cancer (NSCLC) by the targeted therapies or personalized medicine.